secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibrx, Inc. (—)
CIK:        0001739614
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001739614-24-000031
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibrx reports Q1 results; Sanofi merger with $30/shr cash, CVR, and spin-off set for May 30
--------------------------------------------------------------------------------

- Sanofi to acquire INBRX-101 assets; shareholders receive $30/shr cash + $5 CVR + 1/4 share of New Inhibrx.
- Merger closing and spin-off expected May 30; special meeting May 24; when-issued trading of New Inhibrx (INXB) starts May 16.
- Q1 net loss $78.7M ($1.44/shr) vs $48.9M ($1.12/shr) YoY; R&D expense up 71% to $63.9M.
- Cash $252.5M at Mar 31, down from $277.9M at Dec 31; $38.7M in stock option proceeds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739614/000173961424000031/0001739614-24-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739614/000173961424000031/inhibrx-20240509.htm
  HTML page:      https://secwatch.observer/filing/0001739614-24-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer